Logo Medical Science Monitor Basic Research

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Basic Research Logo Medical Science Monitor Basic Research Logo Medical Science Monitor Basic Research

23 May 2025 : Laboratory Research  

Enhanced Tumor Targeting with Midazolam-Loaded PLGA Nanoparticles: An In Vivo Analysis of Safety and Efficacy

Jinghua Jiao ABDFG 1*, Lu Ye ADEF 2, Yuheng Wang ABE 1, Jingdong Li BCFG 3

DOI: 10.12659/MSMBR.949761

Med Sci Monit Basic Res 2025; 31:e949761

Abstract

0:00

BACKGROUND: Midazolam, a commonly used sedative, faces challenges in cancer therapy due to its central nervous system (CNS) toxicity and suboptimal targeting of tumor sites. This study explores the use of poly (lactic-co-glycolic acid) (PLGA) nanoparticles to enhance the delivery of Midazolam, aiming to improve antitumor efficacy while minimizing CNS toxicity.

MATERIAL AND METHODS: We developed Midazolam-loaded PLGA nanoparticles (Midazolam PLGA NPs) using the ultrasonic emulsification-solvent evaporation technique. These nanoparticles were thoroughly characterized for particle size, polydispersity index (PDI), zeta potential, encapsulation efficiency, drug loading, and stability. We assessed cellular uptake and cytotoxicity via the MTT assay, while organ accumulation was quantified using high-performance liquid chromatography-mass spectrometry (HPLC-MS). The safety profile was evaluated by monitoring body weight changes in A549 tumor-bearing mice.

RESULTS: The Midazolam PLGA nanoparticles exhibited a spherical shape, uniform size, high encapsulation efficiency, and excellent colloidal stability. In vitro release studies indicated that 62.51% of Midazolam was released within 24 hours. Enhanced cellular uptake was noted for the nanoparticles in comparison to the solution, with significant accumulation at tumor sites and increased free drug release. The nanoparticles effectively killed tumor cells while sparing normal tissues, demonstrating superior antitumor activity compared to the Midazolam solution. Importantly, treated mice maintained stable body weight, suggesting a favorable safety profile.

CONCLUSIONS: Midazolam-loaded PLGA nanoparticles present a promising approach for targeted cancer therapy. They enhance encapsulation, stability, and selective tumor cell cytotoxicity, resulting in greater antitumor efficacy with minimal adverse effects compared to conventional Midazolam solutions.

Keywords: Midazolam, Nanoparticles, Tumor Cells, Cultured, Animals, Polylactic Acid-Polyglycolic Acid Copolymer, Mice, Humans, Particle Size, A549 cells, Drug Delivery Systems, Drug Liberation, Cell Line, Tumor, Drug Carriers, Neoplasms

Add Comment 0 Comments

Most Viewed Current Articles

13 Apr 2020 : Original article   19,586

Outcome of 24 Weeks of Combined Schroth and Pilates Exercises on Cobb Angle, Angle of Trunk Rotation, Chest...

DOI :10.12659/MSMBR.920449

Med Sci Monit Basic Res 2020; 26:e920449

20 Apr 2018 : Original article   17,466

Brain Training Games Enhance Cognitive Function in Healthy Subjects

DOI :10.12659/MSMBR.909022

Med Sci Monit Basic Res 2018; 24:63-69

23 Jul 2016 : Review article   10,353

Cardiac Hypertrophy: An Introduction to Molecular and Cellular Basis

DOI :10.12659/MSMBR.900437

Med Sci Monit Basic Res 2016; 22:75-79

10 Aug 2020 : Clinical Research   9,788

Effects of Cognitive Task Training on Dynamic Balance and Gait of Patients with Stroke: A Preliminary Rando...

DOI :10.12659/MSMBR.925264

Med Sci Monit Basic Res 2020; 26:e925264

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor Basic Research eISSN: 2325-4416
Medical Science Monitor Basic Research eISSN: 2325-4416